When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk retains a strong market position in a high-growth industry, with P/E multiples poised to expand. See why NVO ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The Danish crown weakened on Friday, after disappointing results from a late-stage trial of a new weight-loss drug drove a ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Construction has already begun on the Ozempic-producer’s new Denmark production facility and 40,000m2 warehouse.

Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...